AMP
Top Five Articles on 360Dx Last Week: AMP Petitions Congress; Universal Dx Funding; More
Last week, readers were most interested in a story about the Association for Molecular Pathology's petition to Congress about CLIA updates and LDTs.
AMP Petitions Congress to Revisit CLIA Update, Eyes Legal Action Against New Proposed FDA LDT Rule
While AMP asked members to register their opposition officially, one official said "there probably will be a lawsuit."
ChromaCode Lung Cancer Assay Shows Advantages in New Data at AMP as Company Eyes Next Applications
Premium
The firm is working with early adopters of its NSCLC kit as it develops new tests for cancer minimal residual disease monitoring and kidney transplant rejection.
A comparison for 144 solid tumor samples showed a "high degree of alignment" with FoundationOne CDx and better calling of CNAs than Illumina's TSO 500.
Medicare contractors want to rein in inappropriate use of genetics tests, but lab and pathologist groups worry that new coverage requirements may limit access.